The Clinical Trials Research Unit (CTRU) in our hospital coordinates a wide range of clinical trials in cancer. The CTRU was established in 2000 and has opened over 150 clinical trials involving over 1,500 patients. 

What is a clinical trial?

Research discoveries in the laboratory may lead to new drug developments. Clinical trials are then conducted to establish and confirm that these new drug treatments are safe and effective when administered to patients in a controlled hospital environment. You may be asked to join clinical trials/research studies if you have a cancer diagnosis requiring drug treatment.

“Adding new treatments to existing standards of care … may often improve an individual persons cancer outcome and overall survival.” 

Professor John McCaffrey, Consultant Oncologist & Medical Director of the CTRU.

“I was monitored a lot by the Clinical Trials team… there is that extra level of care and attention due to being on a trial.” 

Diane Hanly, Mater Misericordiae University Hospital Clinical Trial Patient & Chairperson of the Clinical Trials Ireland.

An experienced team you can trust

The Mater Hospital CTRU is well established and has an experienced and committed team working to improve the outcomes for patients with cancer. The CTRU team includes consultant medical and radiation oncologists and heamatologists, research nurses, pharmacists and administration staff.

The Clinical Trials Research Unit team includes:

  • 1 clinical trials manager
  • 5 specialist research nurses
  • 1 clinical trials pharmacist
  • 4 data managers
  • A business manager and an administrator
  • 8 consultant principal investigators

CTRU Information

Our principal investigators

Oncology/Radiation Consultants:

Prof John. McCaffrey

Dr. Catherine Kelly

Prof Michaela Higgins

Dr. Michael Maher

Dr. David Gallagher

Haematology Consultants:

Prof Peter O’Gorman

Dr. Anne Fortune

Dr. Michael Fay

Our open clinical trials

Select a cancer type below to view our open clinical trials and studies.

Breast cancer clinical trials

Cancer sub-typeStudy nameFull title of study
Early Hormone positive/Her 2 Negative ICORG 14-11 M028048 / PENELOPE B Phase III study evaluating palbociclib (PD‐0332991), a Cyclin‐Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone‐receptor‐positive,HER2‐normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy.
Metastatic Her 2 positive ICORG 14-21 PUMA-NER-3101 (NALA) Randomized, multi-center, multinational, open-label, active-controlled, parallel design study of the combination of neratinib plus capecitabine versus the combination of lapatinib plus capecitabine in HER2+ MBC patients who have received two or more prior HER2 directed regimens in the metastatic setting.
Metastatic Hormone positive/Her 2 Negative ICORG 14-22 Bay BC Ra233 Bayer 16298 Radium Breast Study A Phase II randomized, double-blind, placebo-controlled trial of Radium-223 Dichloride vs placebo when administered to Her2 neg hormone receptor positive breast cancer with bone metastases treated with standard of care hormonal treatment.
Metastatic Triple Negative ICORG 15-33 MERCK MK-3475-119  Breast A randomised Open-Label Phase III study of Single Agent Pembrolizumab versus treatment of Physician's Choice monotherapy for metastatic triple negative Breast Cancer (mTNBC)-(KEYNOTE-119).
BRCA positive ICORG 14-01 BIOMARIN BMN 373-301 TRIO 023 A Phase 3, Open-Label, Randomised, Parallel, 2-Arm, Multi-Center Study of BNM 673 versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, who have progressed no more than 2 prior chemotherapy regimens for Metastatic Disease.
Translational/Observational ICORG 12-40 EORTC 10085 Male breast Cancer Clinical and biological characterisation of Male Breast Cancer: an international EORTC, BIG, TBCRC and NABCG intergroup study. (Part B Prospective).

Gastro-Intestinal cancer clinical trials

Cancer sub-typeStudy nameFull title of study
Primary Liver Cancer (Hepatocellular) ICORG 14-17 Exelixis XL184-309 CELESTIAL A Phase 3 Randomised Double Blind Controlled Study Of Cabozantinib (XL184) vs Placebo In Previously Treated Subjects With Hepatocellular Carcinoma.
Translational/Observational ICORG 08-40 SNP Correlation of Single Nucleotide Polymorphism (SNP) profile of domain III of EGFR to skin and/or eye toxicity and disease response to treatment with Cetuximab or Panitumumab.

Leukemia cancer clinical trials

Cancer sub-typeStudy nameFull title of study
Relapsed Leukaemia   Millennium/Takeda P2001 - PEVONEDISTAT Study A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk
Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.

Lung cancer clinical trials

Cancer sub-typeStudy nameFull title of study
Early Lung Cancer ICORG 15-40 MK3475-091 (EORTC 1416- LCG, PEARLS) early stage NSCLC study  A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS).
Metastatic Lung Cancer ICORG 12-53 / ETOP SPLENDOUR Randomised Phase 3 trial evaluating the addition of Denosumab to standard first-line anticancer treatment in advanced NSCLC.

Lymphoma cancer clinical trials

Cancer sub-typeStudy nameFull title of study
Untreated Lymphoma ICORG 15-08 / cc-5013-dlc-002 / ROBUST (Celgene)  Phase 3 Randomized, double-blind, placebo-controlled, multicenter study to compare the efficacy and safety of Lenalidomide (CC-5013) plus R-CHOP Chemotherapy (R2-CHOP) verus placebo plus R-CHOP Chemotherapy in subjects with previously untreated activated B-Cell Type Diffuse Large B-Cell Lymphoma.
Relapsed Lymphoma ICORG 15-38 Bayer 17067/CHRONOS 3/Phase III A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL) – CHRONOS-3 (Bayer 17067).
Translational/Observational ICORG 15-09 MILLENNIUM ARROVEN  MILLENNIUM ARROVEN Post-Authorization Safety Study (Brentuximab vedotin in R/R Hodgkins Lymphoma).

Melanoma cancer clinical trials

Cancer sub-typeStudy nameFull title of study
Metastatic Malignant Melanoma BMS209-401 Melanoma Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma.

Myeloma cancer clinical trials

Cancer sub-typeStudy nameFull title of study
Untreated Myeloma ICORG 15-11 MAIA MMY3008 Janssen-Cilag A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy.
Untreated Myeloma ICORG 12-02/ECOG E3A06  Randomised Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma.
Relapsed Myeloma ICORG 15-10 Celgene CC-4047 MM-007 - 0451-0098 Optimism A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM).

Ovarian cancer clinical trials

Cancer sub-typeStudy nameFull title of study
Untreated Ovarian ICORG 11-29 ICON 8 B a randomised controlled trial comparing weekly chemotherapy +/- bevacizumab to standard 3-weekly chemotherapy + bevacizumab for women with recently diagnosed ovarian cancer.
Relapsed Ovarian ICORG 15-22 Pfizer B9991009 Javelin Ovarian 200 Ireland   A Phase 3, Multicenter, Randomized, Open-label study of Avelumab (MSB0010718C) alone or in combination with Pegylated Liposomal Doxorubicin versus Pegylated Liposomal Doxorubicin alone in patients with Platinum-Resistant/Refractory Ovarian Cancer.

Prostate cancer clinical trials

Cancer sub-typeStudy nameFull title of study
Early Prostate ICORG 14-07 ANZUP/ENZARAD A Randomised phase III trial of radiation plus androgen deprivation therapy with or without Enzalutamide for high risk, clinically localised, prostate cancer.
Metastatic Prostate ICORG 13-21 Radium 223 ICORG 13-21 A Phase II Study of Radium-223 in Combination with Enzalutamide in Progressive Metastatic Castrate-Resistant Prostate Cancer.
Metastatic Prostate ICORG 13-09 / GETUG-AFU 21 / PEACE-1  A prospective randomised phase III study of androgen deprivation therapy with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer.
Metastatic Prostate ICORG 14-06 ANZUP 1304 / ENZAMET Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer.
Translational/Observational ICORG 14-04 iPROSPECT  Irish Programme for Stratified Prostate Cancer Therapy (iPROSPECT)
Translational/Observational Astellas 9785-MA-1002 PREMISE Amulti centre non-interventional study across Europe and Africa that seeks to understand the effectiveness and impact on selection of patients for enzalutamide treatment, pain and use of analgesics, quality of life of patients, health resource usage and safety in metastatic Castration Resistant Prostate Cancer (mCRPC) patients.
Translational/Observational ICORG 15-21 ExPeCT Translation study  The ExPeCT Trial (Exercise, Prostate cancer and Circulating Tumour cells). Evasion of immune editing by circulating tumour cells is an exercise-modifiable mechanism underlying aggressive behaviour in obese men with prostate cancer.

Contact us

Clinical Trials & Research Studies

Cancer medicine (oncology)

For information on our open or upcoming clinical trials, please contact our Clinical Trials Research Unit.

Further useful information

For information on clinical trials in Ireland see: